Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Reasonable-zone remains at 15% in Japan

This article was originally published in Clinica

Executive Summary

Japan's "reasonable zone" for discounting Special Treatment Materials prices is to remain at 15%, under the revised reimbursement scheme effective this month. However, industry has had "no firm commitment from the Japanese government that the R-zone will stay at 15%" when the next round of reimbursement revisions takes place in 1998, US industry association HIMA told Clinica. As Clinica went to press, HIMA was testifying on Capitol Hill to a Ways and Means Committee on trade with Japan. The R-zone was one of the main issues under discussion.

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

MT087758

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel